The Filing Desk

Niagen Bioscience

NAGE · Nasdaq · Consumer Staples · Financials, fiscal 2016 to 2025

NAGE · Last close · November 13, 2026
$2.06
Value Niagen Bioscience yourself

Niagen Bioscience's revenue rose 29.9% to $129 million in fiscal 2025. Its operating margin was 12.6%, up from 7.8% a year earlier. It paid out $0 million in dividends and buybacks. The diluted share count rose 9.4%.

NIAGEN BIOSCIENCE, INC. Latest fiscal year ended December 31, 2025 10-K filed March 4, 2026 · 0001386570-26-000013 Updated
Revenue
$129M
29.9%
Operating margin
12.6%
4.8 pts
Net income
$17M
103.3%
Free cash flow
—
 
Return on equity
28.4%
5.4 pts
Market cap
$163M
Nov 13 close
P/E
17.2x
On $0.12 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Niagen Bioscience does

Niagen Bioscience sells products built around nicotinamide riboside (NR), a form of vitamin B3 that helps the body make NAD+, a coenzyme found in every cell. It was formerly named ChromaDex and changed its name in March 2025. It says NAD+ levels fall with age, by up to 65% between ages 30 and 70.

It sells Niagen, its brand of NR, as a dietary and food ingredient, and it began selling it in 2013. Since 2017 it has sold Tru Niagen, a dietary supplement sold directly to consumers. In 2024 it launched Niagen Plus products, which contain pharmaceutical-grade Niagen. It also supplies pharmaceutical-grade Niagen to FDA-registered outsourcing facilities and compounding pharmacies abroad, which prepare and distribute injectable Niagen formulations, available only with a prescription.

It says its future success depends largely on sales of Tru Niagen. The company lists a history of operating losses and says it may need more financing.

Its biggest risks, as it describes them

  • Relying largely on sales of one product, Tru Niagen.
  • Competitors that are larger and have more resources, and pressure on its prices.
  • Operating losses in the past, and possibly needing more financing.
  • Depending on its own sales, marketing and distribution capabilities and on key personnel.
  • Not being able to earn money from its products for pharmaceutical uses through partnerships or licensing.
From Niagen Bioscience's annual report on Form 10-K, filed March 4, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2024 to 2025, earnings per share grew 81.8% a year and net income 104.7% a year, as new shares raised the share count by 9% and diluted each share's earnings.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments2820274465
Debt incl. finance leases00000
Net debt (negative means net cash)−28−20−27−44−65
Net debt to EBITDA———−5.2x−3.8x
Debt to equity0.0x0.0x0.0x0.0x0.0x
Interest coverage−492.2x−18,628.0x−2,799.5x7,726.0x16,279.0x
Current ratio2.8x2.6x2.4x3.6x4.9x
Quick ratio2.0x1.8x1.7x3.1x4.4x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Niagen Bioscience's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Niagen Bioscience says to expect

  • Full year 2026: direct website and e-commerce revenueFor the full year 2026, the Company expects direct website revenues to grow by 15% to 20% year-over-year and overall e-commerce to grow by approximately 5% year-over-year.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 4, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $45,616 of Niagen Bioscience shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 14, 2025Ozan PamirChief Financial OfficerBought6,685$6.82$45,616Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score5 of 97 of 96 of 9
Rule of 40———
Altman Z''−7.40−1.313.42
Accruals ratio−22.1%−5.8%4.4%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailPassPass
Cash from operations is positivePassPassPass
Return on assets rosePassPassPass
Cash from operations exceeds net incomePassPassFail
Debt fell relative to assetsFailFailFail
Current ratio roseFailPassPass
Share count didn't riseFailFailFail
Gross margin rosePassPassPass
Revenue rose relative to assetsPassPassPass
F-score5 of 97 of 96 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Niagen Bioscience side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Niagen BioscienceFY2529.9%12.6%——−3.8x6
The Honest CompanyFY25−1.9%−5.0%3.7%———Compare
Nature's Sunshine ProductsFY255.7%5.2%6.0%23.6%−2.4x7Compare
USANA Health SciencesFY258.3%4.0%0.9%———Compare
Nu SkinFY25−14.3%4.4%3.1%6.5%−0.1x7Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue2221324659677284100129
Revenue growth21.1%−2.1%48.9%46.7%28.0%13.8%6.8%16.0%19.2%29.9%
Gross profit10101626354243516283
Research and development2464345566
Operating income−3−16−33−31−20−27−19−6816
Net income−3−11−33−32−20−27−16−5817
Diluted EPS (US$)−0.08−0.26−0.61−0.56−0.33−0.40−0.24−0.070.110.20
Diluted shares (millions)37455557616770757885
Cash flow
Cash from operations−3−10−21−20−11−24−1571214
Capital expenditure2111——————
Free cash flow−4−11−22−21——————
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation1567766546
Balance sheet at fiscal year end
Cash and short-term investments2452319172820274465
Debt incl. finance leases0000000000
Total assets206342403858545568106
Total liabilities1091520222625262230
Shareholders' equity10542720163229284676
Margins and ratios
Gross margin48.0%49.4%50.9%55.7%59.5%61.5%59.4%60.8%61.8%64.3%
Operating margin−13.4%−77.2%−105.1%−67.6%−33.5%−40.1%−25.9%−6.7%7.8%12.6%
Net margin−13.5%−53.7%−105.6%−69.5%−33.6%−40.2%−23.0%−5.9%8.6%13.4%
Free cash flow margin−20.5%−51.8%−70.4%−45.8%——————
Rule of 40 (growth + FCF margin)0.6%−53.9%−21.6%0.9%——————
Return on capital−35.2%−151.4%−389.6%———−246.5%———
Return on equity−38.4%−35.7%−82.2%−135.0%−108.1%−112.7%−54.8%−17.3%22.9%28.4%
Return on assets−15.2%−27.6%−63.5%−78.0%−50.7%−56.4%−29.6%−9.1%13.9%19.9%
Net debt to EBITDA————————−5.2x−3.8x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Niagen Bioscience's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Niagen Bioscience.